Lantern Pharma's LP-184 Phase 1 Trial Shows Positive Cancer Data with AI-Driven Precision Oncology

LP-184 Phase 1 Trial Results

• 💡 Lantern Pharma has released encouraging new data from its LP-184 Phase 1A trial for advanced solid tumors.
• 🎯 The drug candidate, LP-184, demonstrated meaningful clinical activity, including prolonged stable disease and tumor reductions in biomarker-selected patient groups.
• ⚠️ Patients in the trial were heavily pre-treated and had few remaining treatment options, highlighting the urgent unmet need.

Safety and Efficacy Profile

• ✅ The safety profile of LP-184 continues to appear strong, with manageable side effects and no new safety signals detected.
• 📈 Durable disease control was observed in these patients, indicating promising therapeutic potential.

Advancing to Next Clinical Phases

• 🚀 Based on the positive Phase 1A data, Lantern Pharma is advancing LP-184 into multiple Phase 1B/2 trials.
• 🔬 These trials will be guided by precision oncology biomarkers targeting specific cancers with urgent unmet needs.
• 📌 Key indications include pancreatic cancer, glioblastoma, and solid tumors with DNA damage repair deficiencies.

AI-Driven Drug Development Strategy

• 🤖 LP-184 represents a milestone in Lantern Pharma's mission to integrate AI and machine learning into precision oncology.
• ⚡ The company aims to accelerate cancer drug development timelines and improve treatment outcomes through its AI-driven approach.